Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatm
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to
| Condition(s) | Cancer-associated Thrombosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis. |
| Who can participate | Inclusion Criteria: * Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types * Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing. * Estimated life expectancy \> 6 months * Willingness to give an informed consent * Age ≥ 18 years Exclusion Criteria: * Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis) * Superficial vein thrombosis * Refusal of informed consent \> 72 hrs of anticoagulants * Age \< 18 years old |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Ottawa Hospital Research Institute |
| Locations | Ottawa, Ontario, Canada |
| Start date | 2024-12-03 |
| NCT ID | NCT06894576 |
| Official listing | https://clinicaltrials.gov/study/NCT06894576 |